Skip to main content

Blood therapy giant CSL reports better than expected NPAT | CSL (ASX:CSL) Reporting Results

Jessica Amir
August 18, 2021

The biggest blood therapy company in the world and the second biggest vaccine company, CSL (ASX:CSL) reported its FY21 results.

CSL reported its NPAT jumped 13% to US$2.375 billion. This is 2% above market expectations. Profit growth was boosted by CSL’s Seqirus division, its flu vaccine business, which saw a 30% revenue boost. However, CSL’s Behring division, its blood therapy business, was severely impacted by COVID-19 restrictions.

CSL’s group revenue rose 13% to US$10.3 billion, while CSL’s cashflow from operations surged 46% to US$3.6 billion.

CSL declared a final dividend of US$1.18ps (AU$1.61ps), payable on 30th September. CSL’s total full year dividends increased 10% to US$2.22 per share.

CSL’s FY22 outlook views profit to fall between US$2.15 billion to US$2.25 billion.

CSL is a Morgan Stanley, Macquarie, Citi and Credit Suisse HOLD stock. UBS and Morgans have CSL as a BUY stock.

CSL shares surged to $302.80, at its highest level since June. However, traders quickly took profits, and CSL is now trading at $294.83.

Morning Bell 15 April

Grady Wulff
April 15, 2024

7 Minutes with 7 Executives

Bell Direct
April 12, 2024

Weekly Wrap 12 April

Grady Wulff
April 12, 2024

Morning Bell 12 April

Sam Kanaan
April 12, 2024

Morning Bell 11 April

Grady Wulff
April 11, 2024

Morning Bell 10 April

Grady Wulff
April 10, 2024

Morning Bell 9 April

Sam Kanaan
April 9, 2024

Morning Bell 8 April

Grady Wulff
April 8, 2024

Morning Bell 5 April

Sam Kanaan
April 5, 2024

Morning Bell 4 April

Sophia Mavridis
April 4, 2024

Morning Bell 3 April

Grady Wulff
April 3, 2024